Kornimate/medical-research-clean huggingface dataset:
contribution of image fusion in percutaneous left atrial occlusion procédures (fusion image)

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the most common rhythm disorder, affecting 2 to 3 percent of the population. one of the major complications is the occurrence of thromboembolic events, the thromboembolic risk can be predicted by the chadsvasc score. anticoagulant treatment is therefore almost always indicated, however, in view of the target population, anticoagulant treatment is sometimes contraindicated, justifying the appearance of alternative treatment such as occlusion of the left auricle by surgical or percutaneous means, with the placement of a prosthesis in the left auricle. image fusion is a new imaging technique aimed at improving the spatial view of 2d images (made during a catheterization session) by repositioning in real time a 3d model obtained by reconstruction from scanner images of the structure of interest. once the model has been redesigned, it follows all the consequences that the hemodynamicist wants to take and thus guides the gesture as well as possible. the purpose of this project is to evaluate the contribution of image fusion to per cutaneous occlusion procedures of the left atrium. this contribution will be evaluated by comparing the procedure time, the irradiation time, the amount of contrast material used between the procedures performed with the image fusion technique and without this new technique.


Eligibility criteria:
inclusion criteria: * major patient * patient with a collegially selected indication of fag * patient willing to participate in the study exclusion criteria: * minors, adults under guardianship and protected persons * presence of contraindications to the procedure, including the presence of a thrombus in the left atrium * procedure combined with another percutaneous gesture at the same time
effect of botulinum toxin a injection in treatment of recession rt1 and rt2

Conditions: Gingival Recession

Summary: the goal of this study type: clinical trial\] is to learn the effect of botulinum toxin _a injection in treatment of rt1andrt2 gingival recession in lower anterior teeth . primary outcome is keratinzed tissue width. researchers will compare coronally advanced flap with de-epithelized free gingival graft and botulinum toxin-a injection in mentalis muscle with coronally advanced flap with de-epithelized free gingival graft alone . the outcome will be measured at baseline, after 3 months and after 6 mobths _medical history * 3 mm horizontal incisions, then two vertical incisions * deepitheliztion of anatomical papillae * superficial and deep incisions * harvesting dfgg * suturing * botox injection


Eligibility criteria:
inclusion criteria: * single or multiple rt1, rt2 gr patient * patients ≥18 years * systemically healthy, full mouth plaque score, full mouth bleeding score ≤ 15% after phase i therapy * clinical indication and/or patient request for recession coverage * well motivated patients, maintaining oral hygiene throughout study exclusion criteria: * pregnant or lactating women * smokers' patients * teeth with cervical restorations/abrasion. * patients had a systemic condition affect blood components and healing
lime powder regimen (lpr) for prevention of renal stone recurrence

Conditions: Urolithiasis

Summary: lime powder regimen (lpr) is a lime-derived composition enriches with citrate/citric acid and potassium. lpr was invented to treat the renal stone patients with high risk of stone recurrence after stone removal. lpr should have equal or higher efficacy and lower adverse effect than current standard medicine.

lime powder regimen (lpr) is a mixture of lime-derive component with adjuvants containing high concentration of citrate, and moderate amount of potassium, magnesium and antioxidants. lpr was tested and verified to be very less toxic in cell culture and animal models. the clinical trial phase ii showed that lpr reduced urinary metabolic abnormalities that enhance stone formation, such as hypocitraturia, hypokaliuria and acidified urine. adverse effect of lpr was very low.

Eligibility criteria:
inclusion criteria: * renal stone patients who were identified and stone was removed by surgical method. exclusion criteria: * chronic kidney disease, chronic liver disease, history of coronary artery disease, or person who takes any medication that alters urinary metabolic profiles

Keywords: urolithiasis recurrence citrate antioxidants lime powder regimen
co-adapt: adaptive environments and conversational agent based approaches for healthy ageing and work ability

Conditions: Work Related Stress; Psychologic Adaptation

Summary: the purpose of this study is to identify effective methodologies to help people improve their ability to adapt to psychological stress.

the subjects involved will follow a stress management training (smt) to learn some techniques to manage stress in the workplace and to increase the effectiveness of the intervention will use an app and a conversational agent (ca) an artificial intelligence (ai). the purpose of the smartphone application (app) and ca will be to help people identify their thoughts, help them understand their emotions and the events that generated them. the data collected and analyzed will be integrated into artificial intelligence to improve understanding of what people are writing. based on these analyses, it will be possible to identify the many different variables that interact in cases where a subject shows signs of stress related to adapting to change in the work environment and possible resilience factors that contribute to decreasing the state of stress. tests will be administered at the beginning, at the end of the meetings, and 3 months after the end of the sessions. subjects will be divided into various groups to understand whether app and ca have a significant impact in increasing psychological well-being and stress coping strategies.

Eligibility criteria:
inclusion criteria: * whitecollar * normal or moderate levels of anxiety and stress * a sufficient level of education to understand study procedures and be able to communicate with site personnel * at least 40 to 70 years old exclusion criteria: * high levels of depression combined with other psychological risk indices (such as suicidal thoughts) * current use of narcotics or other substances

Keywords: work related stress psychological adaptation
information provision during early gait training post stroke

Conditions: Stroke

Summary: this study examined the feasibility of using implicit and explicit learning approaches during gait rehabilitation in the early phase following stroke. it was a double blind trial (participants and assessors) using a matched pairs design. participants were recruited from an acute stroke unit, and were randomised to receive gait rehabilitation over three consecutive days using either an implicit or explicit approach. guidelines for each were developed empirically, including differences in the amount, timing, and attentional focus of therapists' verbal communication. sessions were recorded and their content analysed to establish concordance with the guidance. clinical measures were taken at baseline and 24 hours post intervention using the berg balance scale and the step test. therapists were able to adhere to the guidance. both approaches were found to be acceptable to both patients and therapists. the findings will be used to design an appropriately powered rct.


Eligibility criteria:
inclusion criteria: * patients receiving rehabilitation for their first episode of stroke which resulted in hemiplegia * able to give informed consent to take part in the study. * currently receiving physiotherapy for the re-education of gait (at minimum is able to stand, weight bear and take one step with assistance of one person). exclusion criteria: * patients with a history of: * any other neurological conditions including previous stroke * any pre-stroke musculoskeletal condition that either: i. limited walking to less than 100 metres and/or ii. resulted in a noticeable gait abnormality and/or iii. required use of a bilateral walking aid (e.g. 2 walking sticks or a walking frame) * patients with marked receptive dysphasia (not able to follow 3-stage commands) - confirmed through liaison with multi-disciplinary team, including speech and language therapists where necessary
pharmacokinetics of anacetrapib (mk0859) in patients with hepatic insufficiency (mk-0859-039)

Conditions: Dyslipidemia

Summary: this study will evaluate the area under the curve (auc(0 to infinity)) of anacetrapib.


Eligibility criteria:
inclusion criteria: * female subjects of reproductive potential test negative for pregnancy and agree to use two acceptable methods of birth control throughout the study * subject is in good health * subject agrees to refrain from consumption of red wine, grapefruit, orange and apple juices throughout the study exclusion criteria: * patient has a history of cancer * patient is a nursing mother * patient is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study * patient consumes excessive amounts of alcohol or caffeine * patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks

Keywords: hepatic insufficiency
evaluation of a new navigation system in computer-assisted total knee arthroplasty

Conditions: Gonarthrosis

Summary: evaluation of a new navigation system in computer-assisted total knee arthroplasty.

single-blind, randomised, prospective comparative study in two parallel groups (conventional or computer-assisted arthroplasty). the patient will be evaluated during 3 visits: inclusion d0 (before arthroplasty), m3 (intermediate visit 3 months after arthroplasty) and m12 (final visit 12 months after arthroplasty).

Eligibility criteria:
inclusion criteria: * adult man or woman who has signed the informed consent for participation in the study, * patient with primary uni or bilateral gonarthrosis * for whom an indication for total knee arthroplasty has been given exclusion criteria: * history of fracture, arthroplasty or osteotomy of the knee * severe preoperative laxity warranting a constrained prosthesis * inflammatory rheumatic disease or any other progressive concomitant condition that may impact on the patient's functional prognosis * traumatic articular or extra-articular deformities of the lower limb * neurological disease, after-effects of a stroke * mental deficiency or any other reason that may hinder the understanding or the strict application of the protocol * patient not affiliated to the french social security system * patient under legal protection, guardianship or curatorship * patient already included in another therapeutic study protocol or having participated in another trial in the previous three months
pharmaco-epidemiological description of the population treated with aptivus under market conditions, safety & efficacy

Conditions: HIV Infections

Summary: to obtain information on clinical practices for patients treated by aptivus in real life


Eligibility criteria:
inclusion criteria: * hiv positive patients for whom aptivus treatment is initiated by their physician * aptivus scp respect exclusion criteria: none if the inclusion criteria are respected: observational study
techniques and pitfalls of multi-slice ct coronary angiography

Conditions: Computed Tomography Angiography; Coronary Artery Disease

Summary: the goal of this study is to describe the techniques for coronary multi-slice ct angiography and to illustrate the spectrum of artifacts that can simulate coronary artery stenosis and lead to non-assessable segments using 128- and 160 multi-detector row ct scanners and discuss post-processing pitfalls with each. in addition, to review the normal anatomy and anatomic variants of the coronary arteries and discuss effective strategies for improving the diagnostic accuracy of coronary ct angiography.


Eligibility criteria:
inclusion criteria: * male and female patients of at least 18 years of age, with suspected symptomatic cad. exclusion criteria: * un cooperative patients. * those who have allergy to iodinated contrast material or contrast-induced nephropathy, * elevated serum creatinine level (1.5 mg/dl) or creatinine clearance \>60 ml/min. * atrial fibrillation. * aortic stenosis. * percutaneous coronary intervention within the past 6 months. * intolerance to beta-blockers. * body mass index \> 40 * patients with agatston calcium scores of \>400
evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers

Conditions: Diabetes Mellitus, Type 2; Erectile Dysfunction With Diabetes Mellitus; Drug Interaction

Summary: patients with diabetes are three times more likely to develop erectile dysfunction (ed), and longer duration of diabetes is strongly associated with ed. the possibility of pharmacokinetic interactions may occur as the two drugs are metabolized by hepatic cyp3a4 and their co administration may affect their plasma concentrations. the aim of work is to investigate the effect of sildenafil a cyp3a4 substrate and inhibitor on the pharmacokinetics and safety of saxagliptin, a cyp3a4 substrate subjects and methods: eighteen healthy volunteers will be recruited in sequential, single center study to determine pharmacokinetic parameters of saxagliptin, and sildenafil,(auc0→∞), (auc0→t); cmax; tmax; t½, k; ka) will be measured using validated lc-ms/ms method. therapeutic doses will be given to volunteers as follows: sildenafil 50 mg single dose on day 1, then washout period from day 2 till day 8. saxagliptin 5 mg once/day will be given from day 9 till day 12, then on day 13 the two drugs will be co-administered. blood samples (5ml) for pharmacokinetic analysis will be collected on days 1 and 13 for sildenafil as well as on days 12 and 13 for saxagliptin.


Eligibility criteria:
inclusion criteria: 1. age 18-45 years. 2. ideal weight within the normal range according to accepted life tables. 3. non-contributory history and normal physiological examination. 4. laboratory data within normal limits. 5. performance and compliance. 6. the subjects should be without known history of alcohol or drug abuse problems and should preferably be non-smokers. 7. the volunteers will be asked to provide a complete medical history, and complete a physical examination, laboratory tests (hematology, clinical chemistry, urinalysis serology (including hepatitis b surface antigen, anti-hepatitis c virus and antihuman immunodeficiency virus antibody). exclusion criteria: 1. a known hypersensitivity to the drug. 2. gastrointestinal diseases. 3. auto immune diseases. 4. renal diseases or dysfunction. 5. cardiovascular disease of any type. 6. pancreatic disease including diabetes. 7. hepatic disease. 8. hematological, osteopathic, or pulmonary disease. 9. history of alcoholism or drug abuse. 10. serious psychological illness. 11. positive hiv-i. 12. smoking (if including they should be identified). 13. abnormal (out of range) laboratory values. 14. subject who have taken any medication (rx or otc) less than two weeks of the trials starting date. 15. subject who have donated blood or who have been in multiple dosing studies requiring a large volume of blood (more than 500 ml) to be drawn within six weeks preceding the start of the trials. 16. any prior surgery of the gastrointestinal tract that may interfere with drug absorption. 17. treatment with any known enzyme-inducing / inhibiting agents within 30 days prior to the start of the study and throughout the study.
impact of the erigo machine on functional recovery in icu patients

Conditions: Trauma Patients Requiring Physical Rehabilitation

Summary: this study will assess the effects of the erigo applied as part of the early mobilization program in the trauma icu at the university of kentucky. it is our hypothesis, that with the erigo, critically ill patients will tolerate verticalization and mobilization earlier and safely resulting in improved outcomes measured by increased mobility and strength on icu discharge, decreased requirements for mechanical ventilation, reduced complication rates and decreased icu and hospital los.

the "erigo" by hocoma is a combination of tilt table with a robotic stepper device allowing for cyclic leg loading. erigo now also includes functional electrical stimulation to optimize active neuromuscular stimulation. it allows for protected gradual verticalization and mobilization based on patient tolerance and progress. it has been shown to improve orthostatic tolerance, cerebral blood flow and muscle strength. prospective randomized controlled trial will compare two groups. the patients that meet inclusion criteria will be randomized into either the treatment group or a control group. general icu mobility guidelines consist of scaled activity related to the patients' stability. the control group will get the general icu mobility treatments and the treatment group will have one mobility treatment replaced with the erigo treatment.

Eligibility criteria:
inclusion criteria: admission to trauma icu 1. trauma patients requiring physical therapy (including severe traumatic brain injury or polytrauma without extremity fractures or unstable thoracic or lumbar spine fracture 2. burn patients requiring physical therapy 3. gi surgery patients requiring physical therapy 4. necrotizing fasciitis patient requiring physical therapy exclusion criteria: patients with the following conditions: 1. non-weight bearing on lower extremities 2. untreated dvt 3. active hemorrhage 4. leg length \>102cm or \<72cm 5. weight \>135kg 6. systolic bp \> 20mmhg sustained for 10min 7. heart rate \>20bpm outside goal for more than 20min 8. intracranial pressure (icp) \>20mmhg sustained for 10min if applicable, 9. temperature \>38.2c
determination of optimal sleep treatment elements - pilot

Conditions: Insomnia Chronic

Summary: previous research has shown the efficacy of (combinations of) individual components of cognitive behavioral therapy for insomnia (cbt-i), namely sleep hygiene education, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. however, their relative effects, i.e., their effects in direct comparison with each other, are yet to be assessed. in this pilot study, a smartphone and web application developed to treat insomnia using these treatment components will be tested. two future studies will investigate the components' relative efficacy in order to identify the most effective component or combination of components for digitized treatment of chronic insomnia by means of the multiphase optimization strategy (most), and verify this intervention's effect in a randomized controlled trial (rct).

as a pilot study for a multiphase optimization strategy (most) study, the current study will assess the effects of a newly developed smartphone and web application for digitized cognitive behavioural therapy for insomnia (ecbt-i). all treatment components, i.e., sleep hygiene education, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy, will be tested in order to receive feedback on the functioning of the application as well as to get an initial impression of possible treatment effects.

Eligibility criteria:
inclusion criteria: * adults (≥18 years) * individuals who report moderate-to-severe insomnia symptoms (a score ≥10 on the insomnia severity index, isi) * individuals with access to a smartphone or computer with internet connection * individuals who report sufficient technological proficiency (e.g., ability to download apps) exclusion criteria: * children (\<18 years) * individuals who report mild or no clinically relevant insomnia symptoms (a score \<10 on the isi) * individuals who have a shift-work schedule or are on maternity/paternity leave, if this impacts their sleep quality or amount of sleep * individuals who are unable to read danish * individuals who report severe physical or psychological comorbidity with known effects on sleep (e.g., psychosis, cardiovascular disease, cancer, copd) * individuals who report other diagnosed sleep or circadian rhythm disorders (e.g., sleep apnea, narcolepsy) * individuals who have previously used the "hvil®"-app, e.g., during the beta test phase
cbti-cs: a novel cognitive-behavioral treatment for insomnia in cancer survivors

Conditions: Insomnia

Summary: this research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. this is a behavioral intervention study, and no medications are involved.

this study is being done to test the usefulness of a 3-session cognitive-behavioral intervention for improving insomnia in cancer survivors. in this study, the investigators are testing whether this 3-session intervention (cognitive behavior therapy for insomnia in cancer survivors: cbti-cs) will improve insomnia in cancer survivors whose continue to have insomnia symptoms after receiving sleep hygiene education. in addition to the participants who will be offered sleep hygiene education and the 3-session cbti-cs,10 additional participants will be recruited to participate in a pilot evaluation of the cbti-cs intervention delivered via telehealth. this will be a pilot aspect of the study and data from these participants will be for descriptive purposes.

Eligibility criteria:
inclusion criteria: -≥ 18 years of age * history of a cancer diagnosis * no active cancer therapy (excluding chemoprevention) in the past year, and no cancer therapy planned in the next 6 months * no surgery planned in the next 6 months * significant insomnia as evidenced by an insomnia severity index score ≥12 * able to read and write in english * willing to attend study group sessions * motivated and able to follow the demands of the cbti-cs program, to keep sleep records, complete self-report symptom reports and make changes in their sleep schedule, including restricting their sleep. exclusion criteria: * survivors who report ever being diagnosed with bipolar disorder will be excluded. * survivors who report ever being diagnosed with a seizure disorder or have experienced a seizure in the past 12 months will be excluded. * intention to adjust (decrease or increase) use of sedative, hypnotic, or over-the-counter medications that can affect sleep during the study period. * have diagnosed, untreated sleep apnea, or sleep apnea suspected by a physician but which has not been evaluated, or other sleep disorder * employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel that involves adjusting to different time zones, or employment in a position that could impact public safety (such as operating heavy machinery) * refusal to modify or reduce excessive alcohol use that is likely to interfere with an individual's sleep.

Keywords: insomnia cancer survivor